These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Characterization of the biochemical effects of new 1, 8-naphthyridine derivatives, beta-receptor antagonists, in ventricular myocytes. Al jamal JA; Badawneh M Arch Pharm (Weinheim); 2003 Aug; 336(6-7):285-92. PubMed ID: 12953216 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and beta-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3-dihydrothiopyrano[2,3-b]pyridine: identification of beta 3-antagonists. Saccomanni G; Badawneh M; Adinolfi B; Calderone V; Cavallini T; Ferrarini PL; Greco R; Manera C; Testai L Bioorg Med Chem; 2003 Nov; 11(23):4921-31. PubMed ID: 14604653 [TBL] [Abstract][Full Text] [Related]
8. Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint. Perkins JJ; Duong LT; Fernandez-Metzler C; Hartman GD; Kimmel DB; Leu CT; Lynch JJ; Prueksaritanont T; Rodan GA; Rodan SB; Duggan ME; Meissner RS Bioorg Med Chem Lett; 2003 Dec; 13(24):4285-8. PubMed ID: 14643310 [TBL] [Abstract][Full Text] [Related]
9. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. Hutchinson JH; Halczenko W; Brashear KM; Breslin MJ; Coleman PJ; Duong LT; Fernandez-Metzler C; Gentile MA; Fisher JE; Hartman GD; Huff JR; Kimmel DB; Leu CT; Meissner RS; Merkle K; Nagy R; Pennypacker B; Perkins JJ; Prueksaritanont T; Rodan GA; Varga SL; Wesolowski GA; Zartman AE; Rodan SB; Duggan ME J Med Chem; 2003 Oct; 46(22):4790-8. PubMed ID: 14561098 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (I). Khouili M; Guillaumet G; Coudert G; Pujol MD Farmaco; 1996 Mar; 51(3):175-84. PubMed ID: 8688139 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of 1,8-naphthyridine derivatives. Potential antihypertensive agents. II. Da Settimo A; Ferrarini PL; Mori C; Primofiore G; Subissi A Farmaco Sci; 1986 Nov; 41(11):827-38. PubMed ID: 2879740 [TBL] [Abstract][Full Text] [Related]
12. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin. Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080 [TBL] [Abstract][Full Text] [Related]
13. Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization. Nagarajan SR; Lu HF; Gasiecki AF; Khanna IK; Parikh MD; Desai BN; Rogers TE; Clare M; Chen BB; Russell MA; Keene JL; Duffin T; Engleman VW; Finn MB; Freeman SK; Klover JA; Nickols GA; Nickols MA; Shannon KE; Steininger CA; Westlin WF; Westlin MM; Williams ML Bioorg Med Chem; 2007 May; 15(10):3390-412. PubMed ID: 17387018 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and alpha,beta-adrenergic blocking potency of 2,3-dihydro-1,4-benzodioxin derivatives. (II). Khouili M; Guillaumet G; Coudert G; Pujol MD Farmaco; 1996 Mar; 51(3):185-8. PubMed ID: 8688140 [TBL] [Abstract][Full Text] [Related]
15. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking. Yan Y; Li Y; Zhang S; Ai C J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of new compounds with a potential action on the adrenergic system. Merli V; Melloni W; Tamagnone GF; Mascellani G; Andriuoli G; Micheli D; Sarret M; Brufani M Farmaco Sci; 1982 Dec; 37(12):824-35. PubMed ID: 6130000 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationship of some new beta-blocking agents with possible alpha-adrenoreceptor activity. Bergmann J; Takács K Arch Pharm (Weinheim); 1990 Jul; 323(7):387-91. PubMed ID: 1978654 [TBL] [Abstract][Full Text] [Related]
18. (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist. Clark RD; Repke DB; Kilpatrick AT; Brown CM; MacKinnon AC; Clague RU; Spedding M J Med Chem; 1989 Sep; 32(9):2034-6. PubMed ID: 2570150 [No Abstract] [Full Text] [Related]
19. Synthesis and adrenergic properties of new duplicated analogs of methoxamine. Perez F; Rosell G; Mauleon D; Carganico G Farmaco; 1991 Oct; 46(10):1155-66. PubMed ID: 1687722 [TBL] [Abstract][Full Text] [Related]
20. Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies. Kinney WA; Teleha CA; Thompson AS; Newport M; Hansen R; Ballentine S; Ghosh S; Mahan A; Grasa G; Zanotti-Gerosa A; Dingenen J; Schubert C; Zhou Y; Leo GC; McComsey DF; Santulli RJ; Maryanoff BE J Org Chem; 2008 Mar; 73(6):2302-10. PubMed ID: 18278942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]